Page 1 | Search Results | Blood | American Society of Hematology

1-6 of 6

Sort by

Sort Order Select

Journal Articles

A Phase II Trial of Myeloablative I-131-Tositumomab, Etoposide and Cyclophosphamide Followed by Autologous Transplantation for B-Cell Non-Hodgkin's Lymphoma

Ajay K. Gopal, MD, Ted A. Gooley, PhD, Joseph Rajendran, MD, John M. Pagel, MD, PhD, Darrell R. Fisher, PhD, David G. Maloney, MD, PhD, Frederick R. Appelbaum, MD, Andrew Shields, MD, Damian J. Green, MD, Oliver W. Press, MD, PhD

Blood (2012) 120 (21): 811.

https://doi.org/10.1182/blood.V120.21.811.811

Published: 2012

Journal Articles

A Phase I Study of Myeloablative I-131-Anti CD-20 (Tositumomab) Radioimmunotherapy with Escalating Doses of Fludarabine Followed by Autologous Hematopoietic Stem Cell Transplantation (ASCT) for Adults ≥ 60 Years of Age with High-Risk or Relapsed/Refractory B-Cell Lymphoma

Ajay K. Gopal, MD, Ted Gooley, Joseph Rajendran, MD, John M. Pagel, MD, PhD, Darrell R. Fisher, PhD, David G. Maloney, MD, PhD, Frederick R. Appelbaum, MD, Andrew Shields, MD, Oliver W. Press, MD, PhD

Blood (2011) 118 (21): 663.

https://doi.org/10.1182/blood.V118.21.663.663

Published: 2011

Journal Articles

90 Y-Ibritumomab tiuxetan, fludarabine, and TBI-based nonmyeloablative allogeneic transplantation conditioning for patients with persistent high-risk B-cell lymphoma

Ajay K. Gopal, Katherine A. Guthrie, Joseph Rajendran, John M. Pagel, George Oliveira, David G. Maloney, Manuela C. Matesan, Rainer F. Storb, Oliver W. Press

Blood (2011) 118 (4): 1132–1139.

https://doi.org/10.1182/blood-2010-12-324392

Published: 2011

Journal Articles

Y-90-Ibritumomab Tiuxetan, Fluadarabine and TBI Based Non-Myeloablative Allogeneic Transplant Conditioning for High-Risk B-Cell Lymphoma

Ajay K Gopal, MD, Kathrine Guthrie, PhD, Joseph Rajendran, MD, John M. Pagel, MD, PhD, George Oliviera, MD, David G Maloney, MD., PhD, Rainer F. Storb, MD, Oliver W. Press, MD, PhD

Blood (2010) 116 (21): 33.

https://doi.org/10.1182/blood.V116.21.33.33

Published: 2010

Journal Articles

Allogeneic hematopoietic cell transplantation after conditioning with 131 I–anti-CD45 antibody plus fludarabine and low-dose total body irradiation for elderly patients with advanced acute myeloid leukemia or high-risk myelodysplastic syndrome

John M. Pagel, Theodore A. Gooley, Joseph Rajendran, Darrell R. Fisher, Wendy A. Wilson, Brenda M. Sandmaier, Dana C. Matthews, H. Joachim Deeg, Ajay K. Gopal, Paul J. Martin, Rainer F. Storb, Oliver W. Press, Frederick R. Appelbaum

Blood (2009) 114 (27): 5444–5453.

https://doi.org/10.1182/blood-2009-03-213298

Published: 2009

Journal Articles

131I–anti-CD45 antibody plus busulfan and cyclophosphamide before allogeneic hematopoietic cell transplantation for treatment of acute myeloid leukemia in first remission

John M. Pagel, Frederick R. Appelbaum, Janet F. Eary, Joseph Rajendran, Darrell R. Fisher, Ted Gooley, Katherine Ruffner, Eneida Nemecek, Eileen Sickle, Larry Durack, Jeanette Carreras, Mary M. Horowitz, Oliver W. Press, Ajay K. Gopal, Paul J. Martin, Irwin D. Bernstein, Dana C. Matthews

Blood (2006) 107 (5): 2184–2191.

https://doi.org/10.1182/blood-2005-06-2317

Published: 2006

NARROW

A Phase II Trial of Myeloablative I-131-Tositumomab, Etoposide and Cyclophosphamide Followed by Autologous Transplantation for B-Cell Non-Hodgkin's Lymphoma

A Phase I Study of Myeloablative I-131-Anti CD-20 (Tositumomab) Radioimmunotherapy with Escalating Doses of Fludarabine Followed by Autologous Hematopoietic Stem Cell Transplantation (ASCT) for Adults ≥ 60 Years of Age with High-Risk or Relapsed/Refractory B-Cell Lymphoma

90 Y-Ibritumomab tiuxetan, fludarabine, and TBI-based nonmyeloablative allogeneic transplantation conditioning for patients with persistent high-risk B-cell lymphoma

Y-90-Ibritumomab Tiuxetan, Fluadarabine and TBI Based Non-Myeloablative Allogeneic Transplant Conditioning for High-Risk B-Cell Lymphoma

Allogeneic hematopoietic cell transplantation after conditioning with 131 I–anti-CD45 antibody plus fludarabine and low-dose total body irradiation for elderly patients with advanced acute myeloid leukemia or high-risk myelodysplastic syndrome

131I–anti-CD45 antibody plus busulfan and cyclophosphamide before allogeneic hematopoietic cell transplantation for treatment of acute myeloid leukemia in first remission

Email alerts

ASH Publications

American Society of Hematology

A Phase II Trial of Myeloablative I-131-Tositumomab, Etoposide and Cyclophosphamide Followed by Autologous Transplantation for B-Cell Non-Hodgkin's Lymphoma

A Phase I Study of Myeloablative I-131-Anti CD-20 (Tositumomab) Radioimmunotherapy with Escalating Doses of Fludarabine Followed by Autologous Hematopoietic Stem Cell Transplantation (ASCT) for Adults ≥ 60 Years of Age with High-Risk or Relapsed/Refractory B-Cell Lymphoma

90 Y-Ibritumomab tiuxetan, fludarabine, and TBI-based nonmyeloablative allogeneic transplantation conditioning for patients with persistent high-risk B-cell lymphoma

Y-90-Ibritumomab Tiuxetan, Fluadarabine and TBI Based Non-Myeloablative Allogeneic Transplant Conditioning for High-Risk B-Cell Lymphoma

Allogeneic hematopoietic cell transplantation after conditioning with 131 I–anti-CD45 antibody plus fludarabine and low-dose total body irradiation for elderly patients with advanced acute myeloid leukemia or high-risk myelodysplastic syndrome

131I–anti-CD45 antibody plus busulfan and cyclophosphamide before allogeneic hematopoietic cell transplantation for treatment of acute myeloid leukemia in first remission

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only